QRS complex fragmentation and survival following left ventricular assist device implantation.

Permalink
https://escholarship.org/uc/item/0982n4c6

Authors
Thomas, Isac C
Cork, David P
Bhatia, Ankit K
et al.

Publication Date
2015-06-01

DOI
10.1016/j.ijcha.2014.10.017

Peer reviewed
QRS complex fragmentation and survival following left ventricular assist device implantation

Isac C. Thomas, David P. Cork, Ankit K. Bhatia, Hemal M. Nayak, Martin C. Burke, Joshua D. Moss *

Heart Rhythm Center, University of Chicago Medicine, Department of Medicine, Section of Cardiology, Chicago, IL, USA

A R T I C L E   I N F O

Article history:
Received 29 June 2014
Received in revised form 15 September 2014
Accepted 26 October 2014
Available online 12 November 2014

Keywords:
Fragmented QRS
Left ventricular assist device
Mortality
Survival
ECG

A B S T R A C T

Background: In patients with heart disease, the presence of a fragmented QRS complex (fQRS) on the surface electrocardiogram (ECG) is associated with an increased risk of mortality. We sought to evaluate the prevalence and location of fQRS before and after left ventricular assist device (LVAD) implantation and any associated risk of mortality.

Methods and results: Twelve-lead surface ECGs before (pre-LVAD, n = 98) and after (early [<7 days], n = 96, and late [≥30 days], n = 85, post-LVAD) LVAD implantation were evaluated for fQRS. Mortality data were gathered via review of medical records. The prevalence of fQRS increased significantly following LVAD implantation on early post-LVAD ECGs (31% to 47%, p < 0.01). Patients with fQRS in the anterior territory (precordial leads V1 to V5) on late post-LVAD ECGs had decreased survival or survival to cardiac transplantation over a 30 month follow-up period compared with patients who did not exhibit anterior fQRS (30% and 59%, respectively, p < 0.01).

Conclusions: The prevalence of fragmented QRS on 12-lead ECG increases significantly in the anterior territory following LVAD implantation and is associated with decreased survival.

© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Introduction

With advances in technology and design leading to improved patient outcomes, left ventricular assist device (LVAD) support has become a more widely used therapeutic option for patients with advanced heart disease, both as a bridge to cardiac transplantation and destination therapy [1–4]. As LVADs become increasingly utilized, the identification of risk factors that help predict clinical outcomes may improve the post-operative course for these patients. To date, several risk factors associated with adverse clinical outcomes — including thrombocytopenia, hypoalbuminemia, low body surface area, elevated INR, and ventricular arrhythmias — have been identified [5–8].

In prior studies of patients with heart disease, the presence of a fragmented QRS complex (fQRS) on 12-lead surface electrocardiogram (ECG) has been associated with an increased risk of mortality and arrhythmic events [9–11]. The prevalence of fQRS has not been evaluated in a population of patients with LVAD. In this retrospective study, we analyzed 12-lead surface ECGs before and after continuous-flow LVAD implantation for the prevalence and distribution of fQRS, and the association between fQRS and post-LVAD survival.

2. Methods

2.1. Patient selection

The medical records of 107 consecutive adult patients receiving a continuous-flow LVAD (HeartMate-II LVAD [Thoratec, Pleasanton, CA, USA] or HeartWare HVAD [HeartWare, Miramar, FL, USA]) at the University of Chicago from 2008 through 2010 were reviewed.

The HeartMate II is a second-generation continuous-flow device designed to be implanted in the muscles of the abdominal wall or preperitoneally. It has one moving part, the rotor, which is powered by an electromagnetic motor and spins at rates between 6000 and 15,000 rpm [1,12,13]. The HeartWare HVAD is a third-generation continuous-flow device designed to be implanted in the pericardial space adjacent to the heart. It has one moving part, the impeller, which spins at rates between 2400 and 3200 rpm [14,15].

For all patients, implantation of the LVAD was performed in the standard fashion by using a coring instrument to remove a portion of the left ventricular apex, followed by securing of the LVAD inflow cannula through the ventriculotomy and anastomosis of the LVAD outflow graft to the ascending aorta.

2.2. ECG analysis

Archived resting twelve-lead surface ECGs (GE Marquette, GE Healthcare, Milwaukee, WI; USA, 25 mm/s, 10 mm/mV) performed up
to 30-days prior to (pre-LVAD), up to 7-days after (early post-LVAD), and greater than 30-days after (late post-LVAD) LVAD implantation were evaluated for the presence and distribution of fQRS. When multiple ECGs were available, the ECG nearest to LVAD implantation within the above specified intervals was used, unless a preponderance of electromagnetic artifact in the majority of leads (limb or precordial) limited accurate interpretation. In those instances, the next available ECG without artifact in the majority of leads was used. Two investigators independently analyzed ECGs for the presence of fQRS in territories corresponding to major coronary arteries as detailed below. For discrepancies, a third investigator adjudicated the final determination of fQRS presence or absence.

2.3. Fragmented QRS

Criteria for identifying fQRS were adapted from Das et al. [10,16]. Fragmented QRS with a narrow complex was defined by a QRS duration less than 120 ms and the presence of an additional R wave (R') or notching in the S wave in at least two contiguous leads corresponding to a major coronary artery territory [16] (pre- and post-LVAD, Fig. 1a and b). Fragmented QRS with a wide complex was defined by a QRS duration greater than or equal to 120 ms and the presence of more than two R waves, more than two notches in the R wave, or more than two notches in the S wave. In paced QRS complexes, fQRS was defined by the presence of more than two R' waves or more than two notches in the S wave. Findings must again have been present in at least two contiguous leads [10]. Contiguous leads corresponding to major coronary artery territories were designated as anterior (V1 through V5), lateral (I, aVL, and V6), and inferior (II, III, and aVF).

2.4. Survival

Mortality data were gathered through review of medical records on all patients with available pre-LVAD and post-LVAD ECGs up to 30 months after LVAD implantation. Causes of death were recorded when available. The primary outcome was a composite of survival or survival to cardiac transplantation.

2.5. Statistical analysis

Comparisons of continuous variables were performed using the Student paired t-test. Comparisons of categorical variables were performed using the McNemar test and Fisher exact test where appropriate. Comparisons of survival outcomes were determined by analyses of Kaplan–Meier plots. Two-tailed p-values of less than 0.05 were considered statistically significant. Data are presented as mean ± standard deviation or median [interquartile range] where appropriate.

3. Results

Of the 107 patients reviewed, seven were excluded due to the presence of a concomitant RVAD. Two patients did not have available pre-LVAD and post-LVAD ECGs, and were also excluded. The remaining 98 patients were included in the analysis. All 98 patients had available pre-LVAD ECGs, 96 patients had available early post-LVAD ECGs, and 85 patients had available late post-LVAD ECGs. Twelve patients did not survive beyond 30 days.

Baseline patient characteristics are summarized in Table 1. Pre-LVAD ECGs were performed at a median of one (1 to 3) day prior to LVAD implantation, early post-LVAD ECGs at one (0 to 1) day after LVAD implantation, and late post-LVAD ECGs at 83 (38 to 201) days after LVAD implantation.

3.1. Fragmented QRS

The prevalence and distribution of fQRS before and after continuous-flow LVAD implantation are summarized in Table 2. There was 95.6%
concurrence between investigators for presence of fQRS in individual territories on independent review; the remaining 4.4% of fQRS territories were adjudicated by the third investigator. The majority of discrepancies arose in patients with ventricular-paced QRS complexes.

On pre-LVAD ECGs, fQRS was present in at least one territory in 29% of patients. On early post-LVAD ECGs, the prevalence of fQRS increased significantly, with 48% of patients having fragmentation in at least one territory (p < 0.01). The anterior territory was the most frequently fragmented on early post-LVAD ECGs, noted in 32% of patients and significantly increased compared to pre-LVAD ECGs (p < 0.001). The prevalence of fQRS fragmentation on early post-LVAD ECGs in the inferior and lateral territories did not change significantly compared to pre-LVAD ECGs.

On late post-LVAD ECGs, there remained an increase in the prevalence of fQRS in at least one territory as compared to pre-operative ECGs, though the difference was not statistically significant (p = 0.15). The prevalence of fQRS in the anterior territory on late post-LVAD ECGs remained significantly increased compared to pre-LVAD ECGs (26% versus 10%, p = 0.01).

Following LVAD implantation, a smaller proportion of patients were noted to have fQRS on late post-LVAD ECG compared to early post-LVAD ECGs. While some patients developed, and subsequently lost, fQRS post-LVAD, when comparing early post-LVAD and late post-LVAD ECGs, the prevalence of fQRS in at least one territory, as well as the prevalence of fQRS in the anterior territory, did not change significantly (p = 0.57 and 0.73, respectively). There were no significant differences in baseline clinical characteristics between patients with fQRS in at least one territory after LVAD and patients without fQRS after LVAD, both on early post-LVAD and late post-LVAD ECGs (Table 3).

### Table 1
Baseline patient characteristics (n = 98).

| Age (years) | 57 ± 13 |
| Male (%)    | 73     |
| Female (%)  | 27     |
| Ischemic cardiomyopathy (%) | 49  |
| Non-ischemic (%) | 51   |
| Pre-LVAD LVEF (%) | 18 ± 6 |
| HeartMate II LVAD (%) | 83    |
| HeartWare HVAD (%) | 17    |
| Beta blocker use (%) | 17  |
| Amiodarone use (%) | 30   |
| Other antiarrhythmic use (%) | 48   |
| Narrow QRS complex (%) | 35   |
| Wide QRS complex (%) | 65   |
| Ventricularly paced (%) | 53   |

LVEF = left ventricular ejection fraction.

* Values presented as mean ± standard deviation.

### Table 2
Prevalence and distribution of fragmented QRS by territory before and after LVAD implantation.

| Territory       | Pre-LVAD ECG (n = 98) | Early post-LVAD ECG (≤7 days) (n = 96) | p<sup>1</sup> | Delayed post-LVAD ECG (≥30 days) (n = 85) | p<sup>2</sup> | p<sup>3</sup> |
|-----------------|-----------------------|----------------------------------------|--------------|------------------------------------------|--------------|--------------|
| FQRS (any territory) | 28 (29)              | 46 (48)                               | <0.001       | 33 (39)                                 | 0.15         | 0.57         |
| Anterior (V1–V5)  | 10 (10)               | 31 (32)                               | <0.001       | 22 (26)                                 | <0.01        | 0.73         |
| Inferior (II, III, aVF) | 19 (19)           | 23 (24)                               | 0.45         | 21 (25)                                 | 0.80         | 1.00         |
| Lateral (I, aVL, V6) | 12 (12)              | 15 (16)                               | 0.34         | 9 (11)                                  | 1.00         | 0.51         |

<sup>a</sup> Comparison of Pre-LVAD to Post-LVAD.

<sup>b</sup> Comparison of Pre-LVAD to Delayed-post LVAD.

<sup>c</sup> Comparison of Post-LVAD to Delayed-post LVAD.

### Table 3
Clinical characteristics of patients with and without fragmented QRS following LVAD implantation.

| Age (years) | 56 ± 14 | 57 ± 12 | 55 ± 15 | 56 ± 14 |
| Male (%)    | 56      | 41      | 56      | 37      |
| Ischemic cardiomyopathy (%) | 74     | 76      | 79      | 71      |
| Narrow QRS complex (%) | 16     | 18 ± 7  | 17 ± 8  | 17 ± 7  |
| Wide QRS complex (%) | 83     | 84      | 76      | 89      |
| HeartWare (%) | 17     | 16      | 24      | 11      |

LVEF = left ventricular ejection fraction; HeartMate II, Thoratec, Pleasanton, CA; HeartWare HVAD, HeartWare International, Miramar, FL.

* Differences in clinical characteristics not statistically significant (p > 0.05).

#### 3.2. Survival

Mortality data were available for all 98 patients included in the analysis; 42 (43%) survived with the LVAD or survived to cardiac transplantation. The clinical outcomes and causes of death over 30 months are summarized in Table 4. The most common cause of death included sepsis (13%) and intracranial hemorrhage or stroke (10%); it was not available or unknown in 18%.

Patients with an fQRS in the anterior territory (V1–V5) on late post-LVAD ECGs had a significantly decreased rate of survival or survival to cardiac transplantation compared to patients without fQRS in the anterior territory over 30 months (30% and 59%, respectively, p < 0.01, Fig. 2). The causes of death were not significantly different between these two groups (Table 4). Patients with an fQRS in the anterior territory on pre-LVAD and early post-LVAD ECG did not have a significantly different rate of survival compared to their counterparts without fQRS in the anterior territory.

For patients with fQRS in at least one territory on late post-operative ECG, survival was not significantly different compared to the cohort of patients with no fQRS (p = 0.33, Fig. 3). Patients with fQRS in at least one territory on pre-LVAD and early post-LVAD ECGs did not have a significantly different rate of survival compared to their counterparts without fQRS.

Durations of QRS on pre-, early post-, and late post-LVAD ECG were not significantly associated with survival (Table 5). In patients with QRS durations greater than or equal to 120 ms, QRS complex morphology and ventricular pacing were not associated with survival.

#### 4. Discussion

Previous studies have suggested that fractionated intracardiac electrograms are the result of delayed conduction through infarcted, damaged, or ischemic myocardium [17–19]. Similarly, the fragmented
QRS (fQRS) on 12-lead surface ECG has been shown to be a marker of prior myocardial infarction, correlating to regional perfusion abnormalities on myocardial perfusion imaging [16]. In patients with coronary artery disease, fQRS is predictive of increased mortality [9], and in patients with ischemic and nonischemic cardiomyopathy, fQRS is associated with sudden cardiac death and ICD-treated ventricular arrhythmias [11,20].

Patients receiving continuous-flow LVAD in this analysis were commonly found to have fQRS on pre-LVAD ECG, reflective of baseline myocardial disease. However, a significant increase in the prevalence of fQRS was noted following LVAD implantation, both on early and late post-LVAD ECGs. The fQRS was commonly seen in the anterior territory (V1–V5) over 30 months. Patients with fQRS in any territory on late post-LVAD ECGs was associated with decreased survival, suggesting that even in a milieu of significant baseline myocardial disease, new ventricular conduction abnormalities following LVAD implantation may be associated with adverse outcomes. Other alterations in ventricular conduction, including bundle branch blocks and nonspecific intraventricular conduction delays, were not associated with decreased survival in this cohort.

Decreased survival was not seen in patients with fQRS in the anterior territory on early post-LVAD ECGs. Fewer patients had anterior territory fQRS in the late post-LVAD period when compared to the early post-LVAD period, suggesting that changes in ventricular depolarization manifesting as fQRS following LVAD implantation may be transient in some patients, and without associated mortality risk. Long-standing or permanent alterations of conduction properties induced by LVAD implantation may impart an increased risk of adverse outcomes, which in turn may result in a decreased likelihood of survival.

It was not clear from this retrospective analysis how alterations in ventricular conduction, as reflected by the presence of the fQRS

---

**Table 4**  
Survival outcomes over 30 months in patients with continuous-flow LVAD.

| Patients included in survival analysis (n = 98) | Patients with available late post-LVAD ECG (≥ 30 days) | p* |
|-----------------------------------------------|--------------------------------------------------------|----|
| Alive/transplanted 43%                        | Fragmented V1–V5 (n = 23)                              | 26% |
| Expired 57%                                    | Non-fragmented V1–V5 (n = 62)                          | 55% |
| Sepsis 13%                                     |                                                        | 0.03 |
| ICH/stroke 10%                                 |                                                        | 11% |
| Hemorrhage 3%                                  |                                                        | 2%  |
| LVAD 6%                                        |                                                        | 3%  |
| complication                                   |                                                        | 0.12 |
| VA 1%                                         |                                                        | 0%  |
| RHF 1%                                        |                                                        | 2%  |
| Other†                                        |                                                        | 4%  |
| Unknown 18%                                    |                                                        | 18% |

ICH = intracranial hemorrhage; RHF = right heart failure; VA = ventricular arrhythmia.

* 2-Tailed p-value by Fisher exact test for differences between fragmented and non-fragmented V1–V5.

† Based on combined survival and survival to transplant outcome in Kaplan–Meier estimate.

‡ Includes cancer, ARDS, amiodarone toxicity, elective withdrawal of care.

---

**Table 5**  
QRS complex characteristics and median survival (months) in patients with continuous-flow LVAD.

| QRS morphologies | Pre-LVAD | Early post-LVAD | Late post-LVAD |
|------------------|----------|----------------|---------------|
| QRS < 120 ms     | 10.5 [4–30] | 21 [4–30] | 25 [6–30]   |
| QRS ≥ 120 ms     | 30 [3.5–30] | 30 [3.5–30] | 30 [15–30] |
| p                | 0.093     | 0.192         | 0.183        |
| LVBB             | 30 [24–30] | 24 [21–27] | 24 [13–27] |
| RBBB             | 27 [21–28.5] | 22.5 [17–28] | 30 [22.5–30] |
| IVCD             | 30 [22.5–30] | 30 [28.5–30] | 30 [22.5–30] |
| V-paced          | 27 [2.5–30] | 28.5 [2.5–30] | 30 [12–30] |

Values presented as median [interquartile range]. LVBB = left bundle branch block, RBBB = right bundle branch block, IVCD = non-specific intraventricular conduction delay, V-paced = ventricularly paced.

---

**Fig. 2.** Kaplan–Meier survival estimate for patients with and without QRS fragmentation in the anterior territory (V1–V5) over 30 months. Patients with fV1–V5 had a significantly decreased rate of survival or survival to cardiac transplantation (p < 0.01).

**Fig. 3.** Kaplan–Meier survival estimate for patients with and without fQRS fragmentation in any territory (fQRS) over 30 months. Patients with fQRS in any territory on late post-operative ECG did not have a significantly different rate of survival or survival to cardiac transplantation compared to patients without fQRS (p = 0.33).
post-LVAD, might directly contribute to mortality in LVAD-supported patients. The causes of death in patients with and without fQRS in the anterior territory were varied and did not differ significantly between the two groups. In previous studies of patients with heart disease, the fQRS has been associated with an increased risk of sudden cardiac death due to ventricular arrhythmias (VA). While none of the patients with available late post-operative ECGs in this analysis died directly from ventricular arrhythmias (VA), VA following LVAD-implantation has been previously identified as a significant risk factor for increased rates of re-hospitalization and mortality [7,8].

In light of these findings, further study of the fQRS in a prospective population of LVAD-supported patients is merited. The pathogenesis of fQRS in this population is not well understood, and investigations of fQRS development following LVAD implantation may illuminate additional details regarding the nature of conduction system and myocardial muscle alterations following mechanical support. As a potential prognostic indicator of patient outcomes, post-LVAD fQRS may be of clinical utility in the management of LVAD-supported patients.

5. Conclusions

The prevalence of the fragmented QRS complex (fQRS) on 12-lead surface ECG increases significantly following continuous-flow LVAD placement, predominantly in the anterior territory. When fQRS persists on ECGs performed 30-days or more after LVAD implantation, there is an associated decrease in rate of survival or survival to cardiac transplantation over 30 months.

Funding

None.

Conflicts of interest

None declared.

Acknowledgments

None.

References

[1] Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007;357:385–96.
[2] Slaughter MS, Rogers JC, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2005;358:1241–51.
[3] Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous-flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Integrity Registry for Mechanically Assisted Circulatory Support) J Am Coll Cardiol 2011;57:1890–8.
[4] John R, Kandar F, Liao K, Colvin-Adams M, Boyle A, Joyce L. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg 2008;86:1227–34 [discussion 34–5].
[5] Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007;116:497–505.
[6] Cowger J, Sundareswaran K, Rogers JC, Park SJ, Pagani FD, Bhat G, et al. Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. J Am Coll Cardiol 2013;61:313–21.
[7] Brenyo A, Rao M, Koneru S, Hallinan W, Shah S, Massey HF, et al. Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. J Cardiovasc Electrophysiol 2012;23:515–20.
[8] Raasch H, Jensen BC, Chang PP, Mounsey JP, Cehi AK, Chung EH, et al. Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. Am Heart J 2012;164:373–8.
[9] Das MK, Saha C, El Masry H, Peng J, Dandamudi G, Mahenthiran J, et al. Fragmented QRS on a 12-lead ECG: a predictor of mortality and cardiac events in patients with coronary artery disease. Heart Rhythm 2007;4:1185–92.
[10] Das MK, Suradi H, Maskoun W, Michael MA, Shen C, Peng J, et al. Fragmented wide QRS on a 12-lead ECG. Clinical perspective Circ Arrhythm Electrophysiol 2008;1:258–68.
[11] Das MK, Maskoun W, Shen C, Michael MA, Suradi H, Desai M, et al. Fragmented QRS on twelve-lead electrocardiogram predicts arrhythmic events in patients with ischemic and nonischemic cardiomyopathy. Heart Rhythm 2010;7:74–80.
[12] Griffith BP, Kornos RL, Borovetz HS, Litvak K, Antaki JF, Poirier VL, et al. HeartMate II left ventricular assist system: from concept to clinical use. Ann Thorac Surg 2001;71:5116–20.
[13] Frazier OH, Delgado III RM, Kar B, Patel V, Gregoric ID, Myers TJ. First clinical use of the redesigned HeartMate II left ventricular assist system in the United States: a case report. Tex Heart Inst J 2004;31:157–9.
[14] Dell’Aquila AM, Schneider SRB, Schlarb D, Redwan B, Sindermann JR, Ellger B, et al. Initial clinical experience with the HeartWare left ventricular assist system: a single-center report. Ann Thorac Surg 2013;95:170–7.
[15] Rodriguez LE, Suarez EE, Loebe M, Bruckner BA. Ventricular assist devices (VAD) therapy: new technology, new hope? Methodist Debakey Cardiovasc J 2013;9:32–7.
[16] Das MK, Khan B, Jacob S, Kumar A, Mahenthiran J. Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease. Circulation 2006;113:2495–501.
[17] Gardner PI, Ursell PC, Fenoglio JJ, Wit AL. Electrophysiologic and anatomic basis for fractionated electrograms recorded from healed myocardial infarcts. Circulation 1985;72:596–611.
[18] Lesh MD, Spear JF, Simson MB. A computer model of the electrogram: what causes fractionation? J Electrocardiol 1988;21:590–73 [Supplement].
[19] Flowers NC, Horan LG, Thomas JR, Tolleson WJ. The anatomic basis for high-frequency components in the electrocardiogram. Circulation 1960;29:631–9.
[20] Brenyo A, Pietrasik C, Barsheesht A, Huang DT, Polonsky B, McInt S, et al. QRS fragmentation and the risk of sudden cardiac death in MADIT II. J Cardiovasc Electrophysiol 2012;23:1343–8.